Australian antiviral drug development company, Island Pharmaceuticals Ltd (ASX: ILA; Island or the Company) is pleased to announce progress on its ISLA-101 Phase 2a/b clinical trial in dengue fever. All key data samples have been collected following dosing of all subjects in the Phase 2a (prophylactic) trial as part of Island’s ISLA-101 Phase 2a/b PROTECT clinical trial in dengue fever ...
Gunnison Copper (TSX:GCU,OTCQB:EXMGF) is shifting its development strategy for the Gunnison copper project in Arizona, US, laying out plans for a conventional open-pit and heap-leach operation. In a preliminary economic assessment (PEA), released on Thursday (November 14), the company explains that it is targeting the production of finished copper cathode for domestic consumption. The PEA outlines an after-tax net present ...
Provaris Energy Ltd (ASX.PV1, Provaris, the Company) is pleased to present the notice of initial substantial holder. Click here for the full ASX Release This post appeared first on investingnews.com ...